title: Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism.
abstract: Genome-wide association studies (GWAS) have consistently implicated noncoding variation within the TCF7L2 locus with type 2 diabetes (T2D) risk. While this locus represents the strongest genetic determinant for T2D risk in humans, it remains unclear how these noncoding variants affect disease etiology. To test the hypothesis that the T2D-associated interval harbors cis-regulatory elements controlling TCF7L2 expression, we conducted in vivo transgenic reporter assays to characterize the TCF7L2 regulatory landscape. We found that the 92-kb genomic interval associated with T2D harbors long-range enhancers regulating various aspects of the spatial-temporal expression patterns of TCF7L2, including expression in tissues involved in the control of glucose homeostasis. By selectively deleting this interval, we establish a critical role for these enhancers in robust TCF7L2 expression. To further determine whether variation in Tcf7l2 expression may lead to diabetes, we developed a Tcf7l2 copy-number allelic series in mice. We show that a null Tcf7l2 allele leads, in a dose-dependent manner, to lower glycemic profiles. Tcf7l2 null mice also display enhanced glucose tolerance coupled to significantly lowered insulin levels, suggesting that these mice are protected against T2D. Confirming these observations, transgenic mice harboring multiple Tcf7l2 copies and overexpressing this gene display reciprocal phenotypes, including glucose intolerance. These results directly demonstrate that Tcf7l2 plays a role in regulating glucose tolerance, suggesting that overexpression of this gene is associated with increased risk of T2D. These data highlight the role of enhancer elements as mediators of T2D risk in humans, strengthening the evidence that variation in cis-regulatory elements may be a paradigm for genetic predispositions to common disease.
authors.affiliation: Department of Human Genetics, University of Chicago, Chicago, IL 60637, USA. dsavic@uchicago.edu
authors.forename: Daniel
authors.initials: D
authors.lastname: Savic
authors.forename: Honggang
authors.initials: H
authors.lastname: Ye
authors.forename: Ivy
authors.initials: I
authors.lastname: Aneas
authors.forename: Soo-Young
authors.initials: SY
authors.lastname: Park
authors.forename: Graeme I
authors.initials: GI
authors.lastname: Bell
authors.forename: Marcelo A
authors.initials: MA
authors.lastname: Nobrega
mesh_terms: D000483:Alleles; D000818:Animals; D001483:Base Sequence; D001786:Blood Glucose / Q000235:genetics; D022202:Chromosomes, Artificial, Bacterial; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism; D004742:Enhancer Elements, Genetic; D005260:Female; D015870:Gene Expression; D005786:Gene Expression Regulation; D023061:Gene Order; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D053858:Metabolic Networks and Pathways / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D010641:Phenotype; D058118:Transcription Factor 7-Like 2 Protein / Q000235:genetics* / Q000378:metabolism*
chemical_list: D001786:Blood Glucose; D058118:Transcription Factor 7-Like 2 Protein; D005947:Glucose